211 related articles for article (PubMed ID: 16638864)
1. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer.
Damaraju S; Murray D; Dufour J; Carandang D; Myrehaug S; Fallone G; Field C; Greiner R; Hanson J; Cass CE; Parliament M
Clin Cancer Res; 2006 Apr; 12(8):2545-54. PubMed ID: 16638864
[TBL] [Abstract][Full Text] [Related]
2. Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients.
Fachal L; Gómez-Caamaño A; Peleteiro P; Carballo A; Calvo-Crespo P; Sánchez-García M; Lobato-Busto R; Carracedo A; Vega A
Radiother Oncol; 2012 Dec; 105(3):321-8. PubMed ID: 23075580
[TBL] [Abstract][Full Text] [Related]
3. Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy.
Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Serafini F; Cambria R; Vavassori A; Cattani F; Garibaldi C; Gherardi F; Ferrari A; Rocco B; Scardino E; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):26-34. PubMed ID: 20133085
[TBL] [Abstract][Full Text] [Related]
4. Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients.
Langsenlehner T; Renner W; Gerger A; Hofmann G; Thurner EM; Kapp KS; Langsenlehner U
Radiother Oncol; 2011 Mar; 98(3):387-93. PubMed ID: 21345510
[TBL] [Abstract][Full Text] [Related]
5. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
6. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
Kupelian PA; Willoughby TR
Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
[TBL] [Abstract][Full Text] [Related]
7. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
[TBL] [Abstract][Full Text] [Related]
8. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Burri RJ; Stock RG; Cesaretti JA; Atencio DP; Peters S; Peters CA; Fan G; Stone NN; Ostrer H; Rosenstein BS
Radiat Res; 2008 Jul; 170(1):49-59. PubMed ID: 18582155
[TBL] [Abstract][Full Text] [Related]
9. Conformal radiotherapy of clinically localized prostate cancer: analysis of rectal and urinary toxicity and correlation with dose-volume parameters.
Ballare A; Di Salvo M; Loi G; Ferrari G; Beldi D; Krengli M
Tumori; 2009; 95(2):160-8. PubMed ID: 19579861
[TBL] [Abstract][Full Text] [Related]
10. [Acute toxicity in 50 patients with prostate cancer treated with conformal radiation therapy].
Nasr E; Merhej S; Nehme Nasr D; Fares G
J Med Liban; 2001; 49(6):325-8. PubMed ID: 12744634
[TBL] [Abstract][Full Text] [Related]
11. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
12. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
[TBL] [Abstract][Full Text] [Related]
13. Late rectal and urinary toxicity from conformal, dose-escalated radiation therapy for prostate cancer: a prospective study of 402 patients.
Lin C; Turner S; Mai T; Kneebone A; Gebski V
Australas Radiol; 2007 Dec; 51(6):578-83. PubMed ID: 17958696
[TBL] [Abstract][Full Text] [Related]
14. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
[TBL] [Abstract][Full Text] [Related]
15. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
Lee CM; Lee RJ; Handrahan DL; Sause WT
Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875
[TBL] [Abstract][Full Text] [Related]
16. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
Harsolia A; Vargas C; Yan D; Brabbins D; Lockman D; Liang J; Gustafson G; Vicini F; Martinez A; Kestin LL
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1100-9. PubMed ID: 17967304
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in XRCC1, ERCC2, and ERCC3 DNA repair genes, CYP1A1 xenobiotic metabolism gene, and tobacco are associated with bladder cancer susceptibility in Tunisian population.
Feki-Tounsi M; Khlifi R; Louati I; Fourati M; Mhiri MN; Hamza-Chaffai A; Rebai A
Environ Sci Pollut Res Int; 2017 Oct; 24(28):22476-22484. PubMed ID: 28803404
[TBL] [Abstract][Full Text] [Related]
18. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Herrera-Ramos E; Rodríguez-Gallego C; Rodríguez-Melcón JI; Lara PC
BMC Med Genet; 2014 Dec; 15():143. PubMed ID: 25540025
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
